The global Chagas disease market is projected to experience a consistent growth in revenue over the forecast period due to its increasing prevalence. According to the Pan American Health Organization, Chagas disease is endemic in 21 Latin American countries, affecting a total of 6 million people. In the Americas, there are approximately 30,000 new cases, 12,000 fatalities, and 8,600 newborns infected with Chagas disease each year. Additionally, approximately 70 million people in the Americas reside in areas where they are exposed to the risk of contracting this disease, which is expected to contribute to the market's revenue growth during the forecast period.

Chagas disease, also known as American trypanosomiasis, is a neglected tropical illness caused by a group of parasites known as Trypanosoma cruzi. Trypanosoma cruzi, the protozoan responsible for Chagas disease, is a parasitic ailment that is systemic and chronic in nature. The primary mode of transmission of the T. cruzi parasite to humans is through infected triatomine bugs, often referred to as "kissing bugs," which feed on human blood. It can also be transmitted from mother to child through the placenta, blood transfusions, and organ transplants. The disease is characterized by symptoms such as fever, headache, cough, swelling, and abdominal pain. Without proper treatment, Chagas disease can lead to permanent damage to the heart and other vital organs.

Get a sample of the report @

Key players

  • Bayer AG
  • Novartis AG
  • Selva Therapeutics
  • Humanigen, Inc.
  • AstraZeneca plc
  • GSK Plc.
  • Pfizer Inc.
  • Eisai Co Ltd 
  • KaloBios Pharmaceuticals, Inc.
  • Merck and Co.

To know more about the report @

Driving Factors:

  1. High Prevalence in Endemic Regions: Chagas disease is prevalent in Latin American countries, with millions of people affected. This high prevalence drives the demand for diagnostics, treatments, and research.
  2. Increased Awareness: Growing awareness among healthcare professionals and the public about Chagas disease's severity and long-term consequences has led to earlier diagnosis and treatment, boosting market growth.
  3. Government Initiatives: Government healthcare initiatives and programs in endemic regions that focus on controlling and eradicating Chagas disease create a favorable environment for market growth.
  4. Rising Research Activities: Increased research efforts to develop new diagnostic tools, treatments, and vaccines for Chagas disease contribute to market expansion.


  1. Limited Diagnostic Accuracy: Existing diagnostic methods for Chagas disease have limitations in terms of accuracy, leading to misdiagnosis or delayed diagnosis.
  2. Lack of Access to Healthcare: In many endemic regions, access to healthcare is limited, which hinders early diagnosis and treatment, impacting the market negatively.
  3. Complexity in Treatment: The chronic nature of Chagas disease often requires prolonged treatment regimens with potentially toxic medications, which can deter patients from seeking treatment.
  4. Financial Constraints: The cost of treatment and medications can be a significant barrier for both patients and healthcare systems, especially in low-income regions.

Request a customization of the report @

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web:

Direct Line: +1-212-710-1370a


Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @

Browse More Latest Reports @